Comparative Pharmacology
Head-to-head clinical analysis: CONRAY versus CONRAY 43.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY versus CONRAY 43.
CONRAY vs CONRAY 43
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iothalamate meglumine is an ionic, high-osmolality radiopaque contrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during radiographic procedures.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
Intravenous: 20-60 mL for CT enhancement; intra-arterial: 5-80 mL per injection; concentration 282 mgI/mL (iothalamate meglumine). Dose based on procedure, body weight, and renal function.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; prolonged in renal impairment.
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal excretion via glomerular filtration; >90% of administered dose eliminated unchanged in urine within 24 hours. Less than 1% biliary or fecal.
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent